Page last updated: 2024-11-10

cerulenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5282054
CHEMBL ID45627
CHEBI ID171741
CHEBI ID94649
SCHEMBL ID41207
MeSH IDM0003925

Synonyms (68)

Synonym
chebi:171741 ,
BRD-K52075040-001-02-2
IDI1_002233
oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2r-(2-alpha,3-alpha(4e,7e)))-
(2r-(2alpha,3alpha(4e,7e)))-3-(1-oxonona-4,7-dienyl)oxirane-2-carboxamide
(2s)(3r)-2,3-epoxy-4-oxo-7,10-dodecadienoylamide
oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2r-(2alpha,3alpha(4e,7e)))-
3-(1-oxo-4,7-nonadienyl)oxiranecarboxamide
(2r,3s)-2,3-epoxy-4-oxo-7e,10e-dodecadienamide
einecs 241-424-8
2,3-epoxy-4-oxo-7,10-dodecadienamide
7,10-dodecadienamide, 2,3-epoxy-4-oxo-
nsc 116069
BSPBIO_001276
cerulenin
(2r,3s)-3-[(4e,7e)-nona-4,7-dienoyl]oxirane-2-carboxamide
helicocerin
oxiranecarboxamide, 3-[(4e,7e)-1-oxo-4,7-nonadienyl]-, (2r,3s)-
17397-89-6
cerulenin, >=98% (hplc), from cephalosporium caerulens
(2r,3s)-3-((4e,7e)-nona-4,7-dienoyl)oxirane-2-carboxamide
(2r,3s)-3-((4e,7e)-nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide
DB01034
NCGC00163492-01
NCGC00163492-02
HMS1990P17
CHEMBL45627 ,
HMS1792P17
HMS1362P17
3-nona-4,7-dienoyl-oxirane-2-carboxylic acid amide(cerulenin)
3-nona-4,7-dienoyl-oxirane-2-carboxylic acid amide
bdbm50009248
BRD-K52075040-001-03-0
BRD-K52075040-001-04-8
(2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide
unii-mf286y830q
mf286y830q ,
1x9 ,
oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2r-(2- .alpha.,3-.alpha.(4e,7e)))-
cerulenin [mi]
(+)-cerulenin
(2r-(2.alpha.,3.alpha.(4e,7e)))-3-(1-oxonona-4,7-dienyl)oxirane- 2-carboxamide
2-oxiranecarboxamide, 3-((4e,7e)-1-oxo-4,7-nonadien-1-yl)-, (2r,3s)-
CCG-208171
G237
smr000058786
MLS006010821
SCHEMBL41207
HMS3403P17
HMS3649F20
(2r,3s)-3-[(4e,7e)-1-oxo-4,7-nonadien-1-yl]-2-oxiranecarboxamide
DTXSID2040995
mfcd00083595
CHEBI:94649
sr-05000002362
SR-05000002362-2
J-010957
CS-6992
HY-A0210
Q5065296
cerulenin, cephalosporium caerulens - cas 17397-89-6
SR-05000002362-3
F85539
oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, [2r-[2a,3a(4e,7e)]]-
nsc764755
nsc-764755
2-oxiranecarboxamide, 3-[(4e,7e)-1-oxo-4,7-nonadien-1-yl]-, (2r,3s)-
Z2311575475

Research Excerpts

Overview

Cerulenin is a fungal toxin that inhibits both eukaryotic and prokaryotic ketoacyl-acyl carrier protein synthases or condensing enzymes. It is a natural product inhibitor of fatty acid biosynthesis and protein palmitoylation.

ExcerptReferenceRelevance
"Cerulenin is a fungal metabolite and a specific inhibitor of fatty acid synthase (FASN), which has shown a potential anticancer activity. "( Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway.
Chen, J; Huang, B; Luo, Y; Lv, S; Song, J; Zhang, Y; Zhao, Y, 2022
)
3.61
"Cerulenin is an effective blocker of the TonEBP actions."( Microglial TonEBP mediates LPS-induced inflammation and memory loss as transcriptional cofactor for NF-κB and AP-1.
Jeong, GW; Kwon, HM; Lee, HH; Lee-Kwon, W, 2020
)
1.28
"Cerulenin is a fungal toxin that inhibits both eukaryotic and prokaryotic ketoacyl-acyl carrier protein synthases or condensing enzymes. "( Structural insights into bacterial resistance to cerulenin.
Altabe, S; Buschiazzo, A; de Mendoza, D; Ficarra, F; Larrieux, N; Schujman, GE; Trajtenberg, F, 2014
)
2.1
"Cerulenin is a natural product inhibitor of fatty acid biosynthesis and protein palmitoylation, through irreversible alkylation of the cysteine residues in the enzymes."( Clickable analogue of cerulenin as chemical probe to explore protein palmitoylation.
Wu, X; Zheng, B; Zhu, S, 2015
)
1.45
"Cerulenin is an antibiotic that inhibits fatty acid synthesis by covalent modification of the active thiol of the chain-elongation subtypes of beta-ketoacyl-acyl carrier protein synthase. "( Subinhibitory cerulenin inhibits staphylococcal exoprotein production by blocking transcription rather than by blocking secretion.
Adhikari, RP; Novick, RP, 2005
)
2.13
"Cerulenin is a potent inhibitor of fatty acid synthase (FAS) in a variety of prokaryotic and eukaryotic cells. "( Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis.
Bishai, WR; Dick, JD; Heine, HS; Kuhajda, FP; Parrish, NM, 1999
)
2.03
"Cerulenin is a fungal mycotoxin that potently inhibits fatty acid synthesis by covalent modification of the active site thiol of the chain-elongation subtypes of beta-ketoacyl-acyl carrier protein (ACP) synthases. "( Response of Bacillus subtilis to cerulenin and acquisition of resistance.
Altabe, S; Choi, KH; de Mendoza, D; Rock, CO; Schujman, GE, 2001
)
2.03
"Cerulenin appears to be a promising new tool of diagnostics for the hitherto unsatisfactorily understood processes of oxygen evolution in photosynthesizing organisms."( Dichlorophenylurea-resistant oxygen evolution in Chlorella after cerulenin treatment.
Herczeg, T; Lehoczki, E; Szalay, L, 1979
)
1.22
"Cerulenin is a powerful inhibitor of viral RNA synthesis, as analyzed by [3H]uridine incorporation, incorporation of [32P]phosphate into viral replication complexes, or Northern blot analysis of viral RNAs hybridized with minus- or plus-stranded riboprobes."( Synthesis of Semliki Forest virus RNA requires continuous lipid synthesis.
Carrasco, L; Guinea, R; Perez, L, 1991
)
1
"Cerulenin is a naturally occurring antibiotic, commonly used as an inhibitor of fatty acid synthesis."( In vitro inhibition of HIV-1 proteinase by cerulenin.
Jupp, R; Kay, J; Knoop, MT; Moelling, K; Nicolaou, G; Pearl, LH; Schulze, T, 1990
)
1.26
"Cerulenin is an antibiotic that inhibits eukaryotic lipid and sterol synthesis and blocks lipid modification of proteins. "( Cerulenin is a potent inhibitor of antigen processing by antigen-presenting cells.
Benacerraf, B; Falo, LD; Rock, KL; Rothstein, L, 1987
)
3.16
"Cerulenin is an antibiotic that interferes with fatty acid synthesis in eukaryotic cells. "( The effect of cerulenin on Moloney murine leukemia virus morphogenesis.
Katoh, I; Luftig, RB; Yoshinaka, Y, 1986
)
2.07

Effects

Cerulenin has been observed to inhibit production of Rous sarcoma virus and murine leukaemia virus by infected cells. It has been widely reported to block protein secretion at sub-MIC levels, an effect that has been postulated to represent interference with membrane function.

ExcerptReferenceRelevance
"Cerulenin has been widely reported to block protein secretion at sub-MIC levels, an effect that has been postulated to represent interference with membrane function through interference with normal fatty acid synthesis."( Subinhibitory cerulenin inhibits staphylococcal exoprotein production by blocking transcription rather than by blocking secretion.
Adhikari, RP; Novick, RP, 2005
)
1.41
"Cerulenin has been observed to inhibit production of Rous sarcoma virus and murine leukaemia virus by infected cells, possibly by interfering with proteolytic processing of viral precursor proteins."( In vitro inhibition of HIV-1 proteinase by cerulenin.
Jupp, R; Kay, J; Knoop, MT; Moelling, K; Nicolaou, G; Pearl, LH; Schulze, T, 1990
)
1.26

Actions

Cerulenin does not inhibit antigen uptake or catabolism as assessed with labeled antigen. It did not inhibit either elongation or desaturation systems in S. S.

ExcerptReferenceRelevance
"Cerulenin did not inhibit either elongation or desaturation systems in S."( Substitution of cellular fatty acids in yeast cells by the antibiotic cerulenin and exogenous fatty acids.
Awaya, J; Ohno, H; Ohno, T; Omura, S, 1975
)
1.21
"Cerulenin does not inhibit antigen uptake or catabolism as assessed with labeled antigen."( Cerulenin is a potent inhibitor of antigen processing by antigen-presenting cells.
Benacerraf, B; Falo, LD; Rock, KL; Rothstein, L, 1987
)
2.44

Treatment

Cerulenin treatment resulted in significant upregulation of cytochrome c (CYCS) by 1.2-fold. S-phase kinase-associated protein-2 (SKP2), a negative regulator of cell cycle, and the lipid metabolic genes (PPARA, RXRA, and ACACB) were significantly downregulated. Treatment did not affect Hsp-70 gene expression in Leghorn male hepatoma and quail myoblast cell lines.

ExcerptReferenceRelevance
"Cerulenin-treated mice exhibited a significant decrease in body weight, triglycerides, leptin, and marrow and subcutaneous fat without changes in serum glucose or calciotropic hormones."( Treatment with an inhibitor of fatty acid synthase attenuates bone loss in ovariectomized mice.
Al Saedi, A; Bermeo, S; Duque, G; Khalil, M; Myers, D; Pang, M; Troen, BR; Vidal, C, 2019
)
1.24
"Cerulenin treatment resulted in significant upregulation of cytochrome c (CYCS) by 1.2-fold, whereas S-phase kinase-associated protein-2 (SKP2), a negative regulator of cell cycle, and the lipid metabolic genes (PPARA, RXRA, and ACACB) were significantly downregulated by -1.59-, -1.8-, -1.83-, and -1.5-fold, respectively, in comparison with untreated cancer cells."( Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells.
Deepa, PR; Krishnakumar, S; Vandhana, S, 2013
)
1.11
"Cerulenin treatment was associated with reduced levels of phosphorylated Akt, activation of p38 and induced caspase-3 cleavage and finally caused apoptosis."( Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells.
Hirano, A; Koda, K; Kosugi, C; Murata, S; Shiragami, R; Shuto, K; Suzuki, M; Tezuka, T; Yamazaki, M; Yoshimura, Y, 2013
)
1.4
"Cerulenin-treated Symbiodinium were found to be taken up by anemone hosts at a significantly depressed quantity in comparison with control Symbiodinium."( Fatty acid and phospholipid syntheses are prerequisites for the cell cycle of Symbiodinium and their endosymbiosis within sea anemones.
Chen, CS; Fang, LS; Lee, HH; Mayfield, AB; Wang, LH, 2013
)
1.11
"Cerulenin treatment did not affect Hsp-70 gene expression in Leghorn male hepatoma and quail myoblast cell lines, suggesting that the observed effect in vivo may be mediated through the central nervous system."( Cerulenin upregulates heat shock protein-70 gene expression in chicken muscle.
Buyse, J; Decuypere, E; Dridi, S, 2013
)
2.55
"Cerulenin and orlistat treatments were found to induce apoptosis and decrease cell proliferation, in addition to inducing the release of mitochondrial cytochrome c and activating caspases-9 and -3."( Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration.
Alberici, LC; Castilho, RF; Catharino, RR; Costa, RA; Graner, E; La Guardia, PG; Ortega, RM; Rossato, FA; Vercesi, AE; Zecchin, KG, 2014
)
1.12
"Cerulenin treatment was associated with reduced levels of phosphorylated Akt in Colon 26 cells, suggesting that inhibition of this signal transduction pathway might be involved in the chemopreventive activity of this compound."( Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice.
Fukunaga, K; Kobayashi, A; Murata, S; Oda, T; Ohkohchi, N; Sasaki, R; Yanagisawa, K, 2010
)
1.37
"Cerulenin treatment resulted in inhibition of lipid biosynthesis, but lipid biosynthetic capabilities remained unaltered in sodium butyrate-supplemented cultures."( Inhibitory effect of cerulenin and sodium butyrate on germination of Candida albicans.
Calderone, RA; Cihlar, RL; Hoberg, KA, 1983
)
1.31
"Cerulenin treatment resulted in a relative increase in phospholipids and mycolic acids in MAC and M."( Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis.
Bishai, WR; Dick, JD; Heine, HS; Kuhajda, FP; Parrish, NM, 1999
)
1.31
"Cerulenin treatment of eggs at the early morula or uncleaved stage for 30 min leads to a marked abnormality at the late veliger stage, and the embryos die before hatching."( Inhibition by cerulenin of RNA and lipid synthesis in Limnaea (mollusc) embryos.
Brahmachary, RL; Ray, B, 1979
)
1.34
"Cerulenin treatment sharply reduced the rates of whole spore protein and RNA synthesis."( Mitochondrial biogenesis during fungal spore germination: effects of the antilipogenic antibiotic cerulenin upon Botryodiplodia spores.
Brambl, R; Josephson, M; Wenzler, H, 1978
)
1.2
"Cerulenin-treated cells failed to reproducibly display detectable levels of all odd-numbered-carbon-chain-length fatty acids observed in untreated cells."( Gas-liquid chromatographic analysis of fatty acid methyl esters of Aeromonas hydrophila, Aeromonas sobria, and Aeromonas caviae.
Canonica, FP; Pisano, MA, 1988
)
1
"Cerulenin-treated cells did not incorporate radioactivity from [1-14C]octanoate into esterified palmitate."( Metabolism of saturated fatty acids by Paramecium tetraurelia.
Honer-Schmid, O; Kaneshiro, ES; Rhoads, DE, 1987
)
0.99
"Pre-treatment with cerulenin followed by the addition of 5-FU increased 5-FU efficacy up to 31-, 87-, and 126-times in SK-Br3, MCF-7 and MDA-MB-231 cells, respectively."( Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
Brunet, J; Colomer, R; Menendez, JA; Ropero, S; Vazquez-Martin, A, 2007
)
0.66
"Treatment with cerulenin of cultures growing at various rates and analysis of the subsequent cell divisions indicate that the antibiotic may block a cell cycle event that precedes the completion of chromosome replication by about 10 min."( Effect of cerulenin on Streptococcus faecalis macromolecular synthesis and cell division.
Carson, D; Daneo-Moore, L, 1978
)
1

Toxicity

ExcerptReferenceRelevance
" The data suggest that differences in intermediary metabolism render tumor cells susceptible to toxic fluxes in malonyl-CoA, both in vitro and in vivo."( Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts.
Chrest, FJ; Frehywot, GL; Han, WF; Kuhajda, FP; Pinn, ML; Pizer, ES; Thupari, J; Townsend, CA, 2000
)
0.31
" Current trends in the treatment of human breast cancer are with drug combinations that result in improved responses as well as the ability to use less toxic concentrations of the drugs."( Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells.
Colomer, R; Lupu, R; Menendez, JA, 2004
)
0.32
" These toxic effects were inhibited by addition of cerulenin."( Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro.
Duque, G; Elbaz, A; Gimble, JM; Rivas, D; Wu, X, 2010
)
0.61

Compound-Compound Interactions

ExcerptReferenceRelevance
" In combination with cerulenin and oxaliplatin, activation of the p53-p21 pathway and p38 occurred in a smaller concentration and finally induced caspase-3 cleavage in a smaller concentration of cerulenin and oxaliplatin."( Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells.
Hirano, A; Koda, K; Kosugi, C; Murata, S; Shiragami, R; Shuto, K; Suzuki, M; Tezuka, T; Yamazaki, M; Yoshimura, Y, 2013
)
0.99

Bioavailability

ExcerptReferenceRelevance
" Moreover, StAR overexpression attenuated the PA-induced reduction of nitric oxide bioavailability by protecting the bioactivity of pAkt/peNOS/NO pathway."( Overexpression of steroidogenic acute regulatory protein in rat aortic endothelial cells attenuates palmitic acid-induced inflammation and reduction in nitric oxide bioavailability.
Li, X; Ning, Y; Qiu, Y; Tian, D; Wang, X; Yin, L; Zhan, Y; Zhi, X, 2012
)
0.38
"Our results showed that StAR attenuated lipid synthesis and uptake as well as PA-induced inflammation and reduction in NO bioavailability in aortic endothelial cells."( Overexpression of steroidogenic acute regulatory protein in rat aortic endothelial cells attenuates palmitic acid-induced inflammation and reduction in nitric oxide bioavailability.
Li, X; Ning, Y; Qiu, Y; Tian, D; Wang, X; Yin, L; Zhan, Y; Zhi, X, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" When isobologram transformations of multiple dose-response analyses were performed to detect in vitro synergy, we concluded that the nature of the interaction between cerulenin and 5-FU in individual breast cancer cells lines generally exhibited sequence-dependency."( Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
Brunet, J; Colomer, R; Menendez, JA; Ropero, S; Vazquez-Martin, A, 2007
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
fatty acid synthesis inhibitorAny pathway inhibitor that inhibits the synthesis of fatty acids.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency18.55690.00529.466132.9993AID1347411
Microtubule-associated protein tauHomo sapiens (human)Potency24.70280.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
glucocerebrosidaseHomo sapiens (human)Potency39.81070.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency31.62280.010039.53711,122.0200AID1469
survival motor neuron protein isoform dHomo sapiens (human)Potency31.62280.125912.234435.4813AID1458
Interferon betaHomo sapiens (human)Potency18.55690.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid synthaseGallus gallus (chicken)IC50 (µMol)13.00006.15007.63008.3700AID1803260
Fatty acid synthaseHomo sapiens (human)IC50 (µMol)13.55330.00772.46245.8000AID270726; AID621312; AID697055
Genome polyprotein Human rhinovirus sp.IC50 (µMol)2,500.00000.00052.98388.2000AID160804
Protease Human immunodeficiency virus 1IC50 (µMol)2.50000.00010.22487.3200AID162514
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
lactate metabolic processFatty acid synthaseGallus gallus (chicken)
fatty acid biosynthetic processFatty acid synthaseGallus gallus (chicken)
positive regulation of appetiteFatty acid synthaseGallus gallus (chicken)
osteoblast differentiationFatty acid synthaseHomo sapiens (human)
glandular epithelial cell developmentFatty acid synthaseHomo sapiens (human)
fatty acid metabolic processFatty acid synthaseHomo sapiens (human)
fatty acid biosynthetic processFatty acid synthaseHomo sapiens (human)
inflammatory responseFatty acid synthaseHomo sapiens (human)
ether lipid biosynthetic processFatty acid synthaseHomo sapiens (human)
neutrophil differentiationFatty acid synthaseHomo sapiens (human)
monocyte differentiationFatty acid synthaseHomo sapiens (human)
mammary gland developmentFatty acid synthaseHomo sapiens (human)
modulation by host of viral processFatty acid synthaseHomo sapiens (human)
cellular response to interleukin-4Fatty acid synthaseHomo sapiens (human)
establishment of endothelial intestinal barrierFatty acid synthaseHomo sapiens (human)
fatty-acyl-CoA biosynthetic processFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
single-stranded DNA bindingFatty acid synthaseGallus gallus (chicken)
fatty acid synthase activityFatty acid synthaseGallus gallus (chicken)
[acyl-carrier-protein] S-acetyltransferase activityFatty acid synthaseGallus gallus (chicken)
[acyl-carrier-protein] S-malonyltransferase activityFatty acid synthaseGallus gallus (chicken)
3-oxoacyl-[acyl-carrier-protein] synthase activityFatty acid synthaseGallus gallus (chicken)
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseGallus gallus (chicken)
fatty acyl-[ACP] hydrolase activityFatty acid synthaseGallus gallus (chicken)
phosphopantetheine bindingFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxybutanoyl-[acyl-carrier-protein] hydratase activityFatty acid synthaseGallus gallus (chicken)
(3R)-3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseGallus gallus (chicken)
enoyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseGallus gallus (chicken)
RNA bindingFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-acetyltransferase activityFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-malonyltransferase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] synthase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
protein bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
fatty acyl-[ACP] hydrolase activityFatty acid synthaseHomo sapiens (human)
phosphopantetheine bindingFatty acid synthaseHomo sapiens (human)
cadherin bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxybutanoyl-[acyl-carrier-protein] hydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
enoyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
fatty acid synthase activityFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cytoplasmFatty acid synthaseGallus gallus (chicken)
Golgi apparatusFatty acid synthaseHomo sapiens (human)
cytosolFatty acid synthaseHomo sapiens (human)
plasma membraneFatty acid synthaseHomo sapiens (human)
membraneFatty acid synthaseHomo sapiens (human)
melanosomeFatty acid synthaseHomo sapiens (human)
glycogen granuleFatty acid synthaseHomo sapiens (human)
extracellular exosomeFatty acid synthaseHomo sapiens (human)
cytoplasmFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (77)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1853635Inhibition of lipid synthesis in Staphylococcus aureus ATCC 29213 at 8 times MIC preincubated for 30 mins followed by [3H]-glycerol and measured after 50 mins by [3H]-glycerol incorporation based beta scintillation counter analysis2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
Design, synthesis, and antibacterial activity of
AID430950Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of lipid synthesis at 8 times MIC treated 5 mins before [3H]glycerol challenge measured after 60 mins by [3H]glycerol incorporation assay2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Design, synthesis, and structure-activity relationships of benzophenone-based tetraamides as novel antibacterial agents.
AID278577Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 96 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID544876Antimicrobial activity against Candida dubliniensis harboring MRR1 CD57B mutant gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID555356Effect on growth in Staphylococcus aureus MN8 at 80.00 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID278576Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID544873Antimicrobial activity against Candida dubliniensis harboring MRR1 CM1 mutant gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID544870Antimicrobial activity against mrr1-deficient Candida albicans by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID1204592Inhibition of thrombin-activated F13-A (unknown origin) in plasma assessed as inhibition of fibrin clot formation after 7 mins by biotin incorporation assay2015European journal of medicinal chemistry, Jun-15, Volume: 98(±) cis-Bisamido epoxides: A novel series of potent FXIII-A inhibitors.
AID380444Antimicrobial activity against Staphylococcus aureus RN450 transfected with plasmid SI-1941 bearing antisense to FabF assessed as drug level at which a zone formation after 18 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
AID160804The compound was tested for its affinity against HIV-2 protease (in vitro)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
HIV protease: a novel chemotherapeutic target for AIDS.
AID104011Activity against Mycobacterium tuberculosis (H37Rv) using the standard BACTEC radiometric growth assay2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
A new class of antituberculosis agents.
AID1363146Induction of autophagy in mouse NIH/3T3 cells assessed as upregulation of p62 expression at 25 to 100 uM after 4 hrs by immunoblot analysis2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel autophagy modulators: Design and synthesis of (+)-epogymnolactam analogues and structure-activity relationship.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID356168Antifungal activity against Candida albicans assessed as hazy zone of inhibition by disk diffusion assay2003Journal of natural products, Aug, Volume: 66, Issue:8
CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.
AID162514The compound was tested for its affinity against HIV-1 protease in vitro1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
HIV protease: a novel chemotherapeutic target for AIDS.
AID554734Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 2 nM2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID406203Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as [2-14C]]malonyl-CoA incorporation into fatty acid at 3000 uM2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID645241Cytotoxicity against monkey MA104 cells after 24 hrs2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID627941Binding affinity to Mycobacterium tuberculosis fatty acid synthase 1 at 350 uM by STD NMR spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.
AID325035Antimicrobial activity against Candida albicans SC5314 after 24 hrs by broth macrodilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.
AID544877Antimicrobial activity against Candida dubliniensis harboring MRR1 CD51-2A mutant gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID380445Inhibition of Staphylococcus aureus FAS22006Journal of natural products, Mar, Volume: 69, Issue:3
Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
AID380446Antimicrobial activity against Staphylococcus aureus MB2865 after 20 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
AID356164Inhibition of FAS in human ZR-75-1 cells by spectrophotometry2003Journal of natural products, Aug, Volume: 66, Issue:8
CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.
AID544875Antimicrobial activity against Candida dubliniensis harboring MRR1 CD57 mutant gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID544879Antimicrobial activity against Candida dubliniensis harboring MRR1 CD57A mutant gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID621312Inhibition of human FAS assessed as synthesis of long chain fatty acids from malonyl CoA after 60 mins by fluorescence assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.
AID1759682Inhibition of lipid synthesis in Staphylococcus aureus ATCC 29213 at 8 times MIC measured by liquid scintillation counter2021European journal of medicinal chemistry, Jul-05, Volume: 2194-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.
AID555387Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 120.00 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID289222Antimicrobial activity against Saccharomyces cerevisiae in synthetic defined media without leucine2007Science (New York, N.Y.), Jun-22, Volume: 316, Issue:5832
An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
AID1457520Antibacterial activity against Bacillus subtilis assessed as inhibition of plasma membrane lipids synthesis at 100 mg/L after 50 mins by [3H]-sodium acetate incorporation assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents.
AID1653413Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by BACTEC radiometric growth assay2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID555355Effect on growth in Staphylococcus aureus MN8 at 120.00 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID270726Inhibition of FAS2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma.
AID357254Antifungal activity against Candida albicans ATCC 900282002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
AID325038Antimicrobial activity against Candida albicans P5 after 48 hrs by broth macrodilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.
AID1457505Antibacterial activity against Bacillus subtilis assessed as inhibition of DNA synthesis at 100 mg/L after 50 mins by [3H]thymidine incorporation assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents.
AID1457525Antibacterial activity against Bacillus subtilis assessed as inhibition of protein synthesis at 100 mg/L after 50 mins by [35S]-methionine incorporation assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents.
AID555388Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 80.00 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID697055Inhibition of FASN in human A375 cells2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID278585Reduced apicoplast DNA/nuclear DNA ratio in Plasmodium falciparum FCK2 at 10 uM after 72 hrs by competitive PCR2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID357253Inhibition of Saccharomyces cerevisiae fatty acid synthase2002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
AID356166Antifungal activity against Candida albicans by microdilution spectrophotometric method in presence of mysteric acid2003Journal of natural products, Aug, Volume: 66, Issue:8
CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.
AID1457510Antibacterial activity against Bacillus subtilis assessed as inhibition of RNA synthesis at 100 mg/L after 50 mins by [3H]-uridine incorporation assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents.
AID356165Antifungal activity against Candida albicans by microdilution spectrophotometric method2003Journal of natural products, Aug, Volume: 66, Issue:8
CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.
AID1894103Inhibition of bacterial FabF/B2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID406444Antiparasitic activity against Plasmodium falciparum2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
AID356163Inhibition of Candida albicans SC5314 FAS by spectrophotometry2003Journal of natural products, Aug, Volume: 66, Issue:8
CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.
AID1457515Antibacterial activity against Bacillus subtilis assessed as inhibition of peptidoglycan synthesis at 100 mg/L after 50 mins by [3H]-N-acetylglucosamine incorporation assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents.
AID1894104Inhibition of bacterial FabH2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID355748Inhibition of Saccharomyces cerevisiae FAS2003Journal of natural products, Apr, Volume: 66, Issue:4
Phenolic compounds from Nymphaea odorata.
AID544878Antimicrobial activity against Candida dubliniensis harboring MRR1 CD51-2B mutant gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID1363137Inhibition of autophagy in mouse NIH/3T3 cells assessed as decrease in LC3-2 to LC3-1 ratio after 4 hrs by immunoblot analysis2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel autophagy modulators: Design and synthesis of (+)-epogymnolactam analogues and structure-activity relationship.
AID71602Inhibition of fatty acid synthase at a concentration of 150 (uM)1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors.
AID334168Inhibition of fatty acid synthase2003Journal of natural products, Jan, Volume: 66, Issue:1
Flavanone glycosides from Miconia trailii.
AID544874Antimicrobial activity against Candida dubliniensis harboring MRR1 CM2 mutant gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID325036Antimicrobial activity against Candida albicans P5 after 24 hrs by broth macrodilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.
AID1204605Inhibition of F13-A in human plasma assessed as inhibition of fibrin clot formation by biotin incorporation assay in presence of 1 mM reduced GSH2015European journal of medicinal chemistry, Jun-15, Volume: 98(±) cis-Bisamido epoxides: A novel series of potent FXIII-A inhibitors.
AID492453Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Antimalarials from nature.
AID406204Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as [2-14C]]malonyl-CoA incorporation into fatty acid at 6000 uM2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID1363141Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability at 25 to 100 uM after 4 hrs by CCK8 assay2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel autophagy modulators: Design and synthesis of (+)-epogymnolactam analogues and structure-activity relationship.
AID645239Antiviral activity against Rotavirus SA11 in MA104 cells assessed as inhibition of viral replication after 24 hrs by immunofluorescent assay and Western blotting analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID325037Antimicrobial activity against Candida albicans SC5314 after 48 hrs by broth macrodilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.
AID223801The compound was tested for the inhibition of p21 palmitoylation at a concentration of 5(ug/mL)1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors.
AID357255Antifungal activity against Cryptococcus neoformans ATCC 901132002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
AID544869Antimicrobial activity against wild-type Candida albicans SC5314 by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID208531Inhibition of human T24 cell proliferation1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors.
AID544871Antimicrobial activity against Candida albicans harboring MRR1 gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID406445Inhibition of Plasmodium falciparum FabB/FabF assessed as C6-acyl carrier protein level by MALDI-TOF mass spectrometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
AID1363138Inhibition of autophagy in mouse NIH/3T3 cells assessed as decrease in LC3-2 to actin ratio after 4 hrs by immunoblot analysis2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel autophagy modulators: Design and synthesis of (+)-epogymnolactam analogues and structure-activity relationship.
AID544872Antimicrobial activity against Candida albicans harboring P639S mutation in MRR1F5 gene by microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.
AID1803260FAS Inhibitory Assay from Article 10.3109/14756366.2012.658786: \\Inhibition of fatty acid synthase by ginkgolic acids from the leaves of Ginkgo biloba and their cytotoxic activity.\\2013Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 28, Issue:3
Inhibition of fatty acid synthase by ginkgolic acids from the leaves of Ginkgo biloba and their cytotoxic activity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (510)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990158 (30.98)18.7374
1990's92 (18.04)18.2507
2000's142 (27.84)29.6817
2010's104 (20.39)24.3611
2020's14 (2.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.22 (24.57)
Research Supply Index6.26 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index50.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews15 (2.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other509 (97.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]